A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Lapatinib is also being studied in the treatment of other types of cancer. It is a type of ErbB-2 and EGFR dual tyrosine kinase inhibitor. Also called GW572016, lapatinib ditosylate, and Tykerb.
Source: NCI Dictionary of Cancer Terms2004-11-22 Date last modified: 2007-03-15Lapatinib Ditosylate